Mark Chilvers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8148731/publications.pdf

Version: 2024-02-01

30	1,892	471061	454577
papers	citations	17 h-index	30 g-index

34	34	34	2177
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ciliary beat pattern is associated with specific ultrastructural defects in primary ciliary dyskinesia. Journal of Allergy and Clinical Immunology, 2003, 112, 518-524.	1.5	282
2	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€“11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	5.2	243
3	Analysis of ciliary beat pattern and beat frequency using digital high speed imaging: comparison with the photomultiplier and photodiode methods. Thorax, 2000, 55, 314-317.	2.7	209
4	The effects of coronavirus on human nasal ciliated respiratory epithelium. European Respiratory Journal, 2001, 18, 965-970.	3.1	159
5	Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults. Thorax, 2003, 58, 333-338.	2.7	122
6	Diagnostic Testing of Patients Suspected of Primary Ciliary Dyskinesia. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 307-314.	2.5	116
7	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2â€“5â€¯years (KLIMB). Journal of Cystic Fibrosis, 2019, 18, 838-843.	0.3	94
8	Dornase alfa for cystic fibrosis. The Cochrane Library, 2016, 4, CD001127.	1.5	91
9	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 802-809.	5.2	89
10	Local mucociliary defence mechanisms. Paediatric Respiratory Reviews, 2000, 1, 27-34.	1.2	86
11	Diagnosing primary ciliary dyskinesia. Thorax, 2007, 62, 656-657.	2.7	64
12	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 755-762.	0.3	62
13	Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 262-266.	0.3	45
14	A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11â€¯years with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 708-713.	0.3	44
15	Longâ€term comparative trial of two different physiotherapy techniques; postural drainage with percussion and autogenic drainage, in the treatment of cystic fibrosis. Pediatric Pulmonology, 2010, 45, 1064-1069.	1.0	38
16	Long-term safety of lumacaftorâ€“ivacaftor in children aged 2â€“5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respiratory Medicine,the, 2021, 9, 977-988.	5.2	28
17	Pleuropulmonary complications of PVLâ€positive Staphylococcus aureus infection in children. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 1372-1375.	0.7	20
18	Cystic fibrosisâ€“related diabetes onset can be predicted using biomarkers measured at birth. Genetics in Medicine, 2021, 23, 927-933.	1.1	17

#	Article	IF	Citations
19	Casting a look at pediatric plastic bronchitis. International Journal of Pediatric Otorhinolaryngology, 2015, 79, 1658-1661.	0.4	14
20	Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. Annals of the American Thoracic Society, 2018, 15, 827-836.	1.5	13
21	Cystic fibrosis adolescent transition care in Canada: A snapshot of current practice. Paediatrics and Child Health, 2012, 17, 553-556.	0.3	11
22	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children â‰¥Â6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis, 2022, 21, 675-683.	0.3	10
23	Matrix-assisted laser desorption/ionization time-of-flight MS for the accurate identification of Burkholderia cepacia complex and Burkholderia gladioli in the clinical microbiology laboratory. Journal of Medical Microbiology, 2020, 69, 1105-1113.	0.7	8
24	Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease. Npj Genomic Medicine, 2022, 7, 28.	1.7	7
25	Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis. Human Vaccines and Immunotherapeutics, 2017, 13, 1254-1260.	1.4	6
26	Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia. International Journal of Neonatal Screening, 2020, 6, 46.	1.2	5
27	Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 57-60.	0.3	4
28	Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings. Open Forum Infectious Diseases, 2016, 3, ofw187.	0.4	3
29	Case 1: Chronic cough in a Vietnamese adolescent: Should we be sweating?. Paediatrics and Child Health, 2011, 16, 465-466.	0.3	1
30	Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine, 2017, 35, 5019-5026.	1.7	1